Zacks Investment Research downgraded shares of NuCana (NASDAQ:NCNA) from a buy rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

A number of other research firms have also weighed in on NCNA. Cowen started coverage on shares of NuCana in a research report on Monday, October 23rd. They issued an outperform rating for the company. William Blair started coverage on shares of NuCana in a research report on Monday, October 23rd. They issued an outperform rating for the company. Citigroup started coverage on shares of NuCana in a research report on Monday, October 23rd. They issued a buy rating and a $23.00 price objective for the company. Finally, Jefferies Group started coverage on shares of NuCana in a research report on Monday, October 23rd. They issued a buy rating and a $25.00 price objective for the company. Five analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average target price of $20.67.

NuCana (NCNA) traded up $0.58 during trading hours on Tuesday, hitting $14.30. 116,318 shares of the stock were exchanged, compared to its average volume of 55,579. The firm has a market capitalization of $455.95 and a price-to-earnings ratio of -44.69. NuCana has a twelve month low of $9.32 and a twelve month high of $19.95.

A number of institutional investors have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. purchased a new stake in NuCana in the third quarter valued at approximately $8,266,000. Perceptive Advisors LLC purchased a new stake in NuCana in the third quarter valued at approximately $3,674,000. Alyeska Investment Group L.P. purchased a new stake in NuCana in the third quarter valued at approximately $2,296,000. Citadel Advisors LLC purchased a new stake in NuCana in the third quarter valued at approximately $1,218,000. Finally, Sphera Funds Management LTD. purchased a new stake in NuCana in the third quarter valued at approximately $919,000. Hedge funds and other institutional investors own 22.27% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/nucana-ncna-downgraded-by-zacks-investment-research-to-hold/1806056.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.